article thumbnail

What’s the Business Model for Artificial Intelligence in Healthcare?

Xconomy

These are heady times for using artificial intelligence to extract insights from healthcare data—in particular, from the tidal wave of information coming out of fields like genomics and medical imaging. This story is part of an ongoing Xconomy series on A.I. in healthcare.

article thumbnail

Some of the Best Reads for Casual Friday: Artificial Intelligence

Xconomy

This week, we’re focusing on artificial intelligence, one of the buzziest fields in tech. Or, maybe instead, it’s a day filled with long lunches and listless Internet surfing, as you seek out all the interesting articles you missed during the week. Here are a. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Human Impact of Machine Learning in Medical Diagnostics & More

Xconomy

Less than two weeks later, scientists at Stanford University said they also had created an artificial intelligence algorithm that could diagnose skin cancer as accurately as a panel of 21 board-certified dermatologists. Think what. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

article thumbnail

Ada-AI Seeks to Build a Diverse Artificial Intelligence Community

Xconomy

Artificial intelligence innovation has become part of our everyday lives—retailers use it to tailor the product recommendations they make; biotech companies hope it can create customized medicine. But its shortcomings, born of human biases, are becoming apparent as well.

article thumbnail

Diffbot’s A.I. Engine Draws Global Map of Machine Learning Expertise

Xconomy

A year ago, the leading Chinese Internet company Tencent Holdings pegged the global number of artificial intelligence researchers and professionals at 300,000 or less—just as the unmet demand for such experts was pushing salary offers to as much as $1 million.

article thumbnail

Five Questions With a16z’s Vijay Pande on AI and Making New Drugs

Xconomy

Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in recent years have become faster and cheaper, accelerating their use by those in the business of discovering and developing new drugs.

article thumbnail

Nervana’s $400M+ Buyout Reflects Key Tech Trend in Machine Learning

Xconomy

On the day after Intel announced its acquisition of San Diego machine learning startup Nervana Systems, investor Steve Jurvetson told me he was feeling a sense of satisfaction about a call he made three years ago, and how it has been playing out.